MRD Testing Revolutionizes Breast Cancer Risk Assessment with New Insights
Molecular residual disease (MRD) testing is gaining prominence in breast cancer management by providing insights that traditional imaging methods cannot. MRD tests, such as the Oncodetect® test, analyze circulating tumor DNA (ctDNA) to detect trace amounts of cancer DNA remaining after treatment. This approach allows for a shift from reactive to proactive, risk-informed management of breast cancer. Recent findings from the NSABP B-59 substudy, presented at the San Antonio Breast Cancer Society and the American Association for Cancer Research, highlight the clinical impact of MRD testing. The study found a strong correlation between post-surgical ctDNA positivity and recurrence risk, with ctDNA-positive patients facing a higher likelihood of distant recurrence. Conversely, patients who tested negative for ctDNA showed favorable outcomes, with most remaining recurrence-free at three years. 
